Researchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for Parkinson's disease from cell-to-cell in the brain.

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

Researchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for Parkinson's disease from cell-to-cell in the brain. In a paper published ...

A major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the spread of brain proteins believed to be responsible for Parkinson's ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

An experimental therapy for Parkinson's disease being developed by ... and also after another alpha-synuclein drug tested in the disease – Biogen's cinpanemab – was abandoned in 2021 after ...

Researchers have discovered a new biomarker for Parkinson’s that could ... did not have misfolded alpha-synuclein, suggesting a different biological basis for their disease.

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...